Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-Aventis signs cancer stem cell research agreement

Sanofi-Aventis signs cancer stem cell research agreement

17th September 2007

Sanofi-Aventis has signed a partnership agreement with the Institute of Haematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences in Tianjin, with the goal of benefiting from the rise in available evidence regarding the role of cancer stem cells.

Through the agreement, the company will look to isolate acute myeloid leukaemia stem cells and manufacture monoclonal antibodies against these cells that could become the foundation for new treatment options in the field of oncology.

One of the largest bodies of its type in China, the Institute of Haematology and Blood Diseases Hospital has been treating blood disease patients for a number of years.

Dr Qi-Min Zhan, vice-president of research at the Chinese Academy of Medical Sciences, said: “This collaboration with a large and well-known pharmaceutical company is a significant progress for the academy.”

“It clearly demonstrates that the work of our scientists on the leading-edge of cancer research is acknowledged.”

He added that the organisation would be proactive in its efforts to participate in other programmes of this type.

Earlier this month, Sanofi-Aventis announced that its first-line treatment for advanced non-small cell lung cancer, Taxotere (docetaxel injection concentrate) gave positive results in clinical trials when compared to vinca-alkaloid-based regimens.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.